Utilizing an integrated approach that combines radioresistant cell models with transcriptomic profiling, our findings point to a previously undercharacterized FOSL1-PRMT1-CAPS signaling axis as a critical contributor to therapeutic resistance in GBM. This evidence concerns the gene CAPS and glioblastoma.